Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants

I. Ticha, J. Hojny, R. Michalkova, O. Kodet, E. Krkavcova, N. Hajkova, K. Nemejcova, M. Bartu, R. Jaksa, M. Dura, M. Kanwal, AS. Martinikova, L. Macurek, P. Zemankova, Z. Kleibl, P. Dundr,

. 2019 ; 9 (1) : 17050. [pub] 20191119

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028750

Grantová podpora
NV16-30954A MZ0 CEP - Centrální evidence projektů

The most common histological subtypes of cutaneous melanoma include superficial spreading and nodular melanoma. However, the spectrum of somatic mutations developed in those lesions and all potential druggable targets have not yet been fully elucidated. We present the results of a sequence capture NGS analysis of 114 primary nodular and superficial spreading melanomas identifying driver mutations using biostatistical, immunohistochemical and/or functional approach. The spectrum and frequency of pathogenic or likely pathogenic variants were identified across 54 evaluated genes, including 59 novel mutations, and the newly identified TP53 loss-of-function mutations p.(L194P) and p.(R280K). Frequently mutated genes most commonly affected the MAPK pathway, followed by chromatin remodeling, and cell cycle regulation. Frequent aberrations were also detected in the genes coding for proteins involved in DNA repair and the regulation and modification of cellular tight junctions. Furthermore, relatively frequent mutations were described in KDR and MET, which represent potential clinically important targets. Those results suggest that with the development of new therapeutic possibilities, not only BRAF testing, but complex molecular testing of cutaneous melanoma may become an integral part of the decision process concerning the treatment of patients with melanoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028750
003      
CZ-PrNML
005      
20210114154956.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-019-53636-x $2 doi
035    __
$a (PubMed)31745173
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ticha, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ivana.ticha@vfn.cz.
245    12
$a A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants / $c I. Ticha, J. Hojny, R. Michalkova, O. Kodet, E. Krkavcova, N. Hajkova, K. Nemejcova, M. Bartu, R. Jaksa, M. Dura, M. Kanwal, AS. Martinikova, L. Macurek, P. Zemankova, Z. Kleibl, P. Dundr,
520    9_
$a The most common histological subtypes of cutaneous melanoma include superficial spreading and nodular melanoma. However, the spectrum of somatic mutations developed in those lesions and all potential druggable targets have not yet been fully elucidated. We present the results of a sequence capture NGS analysis of 114 primary nodular and superficial spreading melanomas identifying driver mutations using biostatistical, immunohistochemical and/or functional approach. The spectrum and frequency of pathogenic or likely pathogenic variants were identified across 54 evaluated genes, including 59 novel mutations, and the newly identified TP53 loss-of-function mutations p.(L194P) and p.(R280K). Frequently mutated genes most commonly affected the MAPK pathway, followed by chromatin remodeling, and cell cycle regulation. Frequent aberrations were also detected in the genes coding for proteins involved in DNA repair and the regulation and modification of cellular tight junctions. Furthermore, relatively frequent mutations were described in KDR and MET, which represent potential clinically important targets. Those results suggest that with the development of new therapeutic possibilities, not only BRAF testing, but complex molecular testing of cutaneous melanoma may become an integral part of the decision process concerning the treatment of patients with melanoma.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a buněčný cyklus $x genetika $7 D002453
650    _2
$a restrukturace chromatinu $x genetika $7 D042002
650    _2
$a oprava DNA $x genetika $7 D004260
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $x genetika $7 D005787
650    _2
$a genetická predispozice k nemoci $x genetika $7 D020022
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a mutace ztráty funkce $x genetika $7 D000073658
650    _2
$a MAP kinasový signální systém $x genetika $7 D020935
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x genetika $x patologie $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a nádory kůže $x genetika $x patologie $7 D012878
650    _2
$a těsný spoj $x genetika $7 D019108
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hojny, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Michalkova, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Kodet, Ondrej $u Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic. Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic. BIOCEV, Charles University, First Faculty of Medicine, Vestec, Czech Republic.
700    1_
$a Krkavcova, Eva $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Hajkova, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Nemejcova, Kristyna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Bartu, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Jaksa, Radek $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Dura, Miroslav $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
700    1_
$a Kanwal, Madiha $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Martinikova, Andra S $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Macurek, Libor $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Zemankova, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kleibl, Zdenek $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 17050
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31745173 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154952 $b ABA008
999    __
$a ok $b bmc $g 1609085 $s 1119930
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 1 $d 17050 $e 20191119 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a NV16-30954A $p MZ0
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace